Biotech entity
Every one of those 1 sits in a single category, pharma. Autism Spectrum Disorder is most often covered alongside Acadia Pharmaceuticals, which appears in 1 of these 1 story. Autism Spectrum Disorder appears in 1 tracked Biotech story from March 16, 2026.
Last mentioned: Mar 16, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. Autism Spectrum Disorder is most often covered alongside Acadia Pharmaceuticals, which appears in 1 of these 1 story. Autism Spectrum Disorder appears in 1 tracked Biotech story from March 16, 2026. The tracked stories average 17 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 13 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Autism Spectrum Disorder. Shared-story counts are live from our verified record — not editorial picks.
A surge in parental demand for off-label treatments for autism spectrum disorder (ASD) has created a significant rift between families and the medical community. While anecdotal reports drive interest in therapies like GLP-1s and Rett syndrome drugs, physicians cite a lack of robust clinical data and potential safety risks as reasons for their reluctance to prescribe.
Autism Spectrum Disorder is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
